Alan B. Bergman - 02 Apr 2026 Form 4 Insider Report for 20/20 Biolabs, Inc. (AIDX)

Reporting relationship: Chief Financial Officer
Issuer ticker: AIDX
Reported as of: 02 Apr 2026
Net transaction value: $0
SEC form: 4
Accepted by SEC: 06 Apr 2026, 17:56:49 UTC
Prior SEC filing: 17 Feb 2026
Source filing: View source filing
Reporting owner signature: s/ Alan B. Bergman

Key filing fact

Alan B. Bergman filed Form 4 for 20/20 Biolabs, Inc. (AIDX) on 06 Apr 2026.

Key facts

This page summarizes Alan B. Bergman's Form 4 filing for 20/20 Biolabs, Inc. (AIDX).
1 reported transaction and 1 derivative row are listed below.
Accepted by SEC: 06 Apr 2026, 17:56.

Change

Previous filing in this sequence was filed on 17 Feb 2026.
Current net transaction value: $0.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reporting Owners (1)

CIK 0001907908 Primary reporting owner

Bergman Alan B.

Relationship: Chief Financial Officer
Address: C/O 20/20 BIOLABS, INC.,, 15810 GAITHER ROAD, SUITE 235, GAITHERSBURG
Signature: s/ Alan B. Bergman
Signature date: 06 Apr 2026

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

AIDX transaction Derivative

Stock Option

Award

Transaction value
Shares: +100,000
Change %
Price: $0.000000^*
Shares after: 100,000
Date: 02 Apr 2026
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 100,000
Exercise price: $1.88
Footnotes: F1

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 1 footnote

Footnote F1

25,000 of the shares subject to the stock option will vest on the first anniversary of the date of grant and the remaining shares will vest in equal monthly installments over the following 36 months, subject to the Reporting Person's continuous service to the Issuer.